Comparative Pharmacology
Head-to-head clinical analysis: AFREZZA versus STARJEMZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFREZZA versus STARJEMZA.
AFREZZA vs STARJEMZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhaled human insulin that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin binds to the insulin receptor, activating tyrosine kinase activity leading to downstream metabolic effects.
STARJEMZA is a monoclonal antibody that inhibits complement component 5 (C5) by binding to it with high affinity, thereby preventing its cleavage into C5a and C5b and the subsequent formation of the membrane attack complex (MAC). This inhibition blocks the terminal complement pathway, reducing complement-mediated cell activation and destruction.
Inhaled powder; initial dose: 4 units per inhalation at each meal, titrated based on blood glucose; maximum 48 units per meal. Administer via Afrezza Inhaler.
100 mg orally twice daily with or without food.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours for insulin component; clinical context: duration of glucose-lowering effect may extend beyond due to receptor binding.
The terminal elimination half-life is approximately 12-15 hours in patients with normal renal function, allowing for twice-daily dosing; half-life is prolonged in renal impairment.
Renal: approximately 60-80% as unchanged drug and metabolites (insulin degradation products). Biliary/fecal: minor, <20%.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination, with biliary/fecal excretion responsible for the remaining 30-40%.
Category C
Category C
Antidiabetic Agent
Antidiabetic Agent